Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473381 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Vilazodone in Major Depressive Disorder
A Phase 4 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,162
- Enrollment target
NCT01473381 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 1,162 participants.
The verdict
NCT01473381, a Phase 4 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,162 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
Interventions
- DRUG Citalopram
- DRUG Vilazodone
- DRUG Placebo to citalopram
- DRUG Placebo to vilazodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,162 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01473381
The ClinicalTrials.gov registry entry for NCT01473381 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Citalopram is the first listed.
NCT01473381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01473381 about?
NCT01473381 is a clinical study titled "Safety and Efficacy of Vilazodone in Major Depressive Disorder". The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
What is the current status of trial NCT01473381?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,162 participants. The study started on 2011-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01473381?
The interventions under investigation include: Citalopram (DRUG), Vilazodone (DRUG), Placebo to citalopram (DRUG), Placebo to vilazodone (DRUG).
Who is sponsoring clinical trial NCT01473381?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.